STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life

BACKGROUND: Asthma patients with obesity often have a high disease burden, despite the use of high-dose inhaled corticosteroids (ICS). In contrast to asthmatics with normal weight, the efficacy of ICS in patients with obesity and asthma is often relatively low. Meanwhile, patients do suffer from sid...

Descripción completa

Detalles Bibliográficos
Autores principales: Witte, Jan A., Braunstahl, Gert-Jan, Blox, Wouter J. B., van ’t Westeinde, Susan C., in ’t Veen, Johannes C. C. M., Kappen, Jasper H., van Rossum, Elisabeth F. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818143/
https://www.ncbi.nlm.nih.gov/pubmed/35123457
http://dx.doi.org/10.1186/s12890-022-01843-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818143/
https://www.ncbi.nlm.nih.gov/pubmed/35123457
http://dx.doi.org/10.1186/s12890-022-01843-0

Ejemplares similares